• -
  • English
  • Japanese
  • Korean
表紙
市場調查報告書
商品編碼
1025320

糖尿病腎病變的全球市場預測(2021年∼2027年)

Diabetic Nephropathy Market 2021-2027
出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球糖尿病腎病變的市場規模，在預測期間內預計以5.3％大幅度的年複合成長率擴大。推動全球糖尿病腎病變市場成長的主要原因，是由於久坐的生活方式和飲食的混亂等，使全球糖尿病患者持續增加。同時，影像診斷設備高額，及臨床試驗需要長期間，成為市場成長的主要的阻礙因素。

COVID-19大流行和中國和美國的貿易戰爭，對全球糖尿病腎病變市場帶來了大幅影響。醫療設備在中國製造，不過，因為全球許多國家與中國進行貿易，中國被認為是COVID-19擴大的原因。因此，供應鏈寸斷，預計帶給市場大幅影響。

本報告提供全球糖尿病腎病變市場相關調查分析，市場概要，市場決策要素，市場區隔，競爭情形，各地區分析，主要企業等相關的系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和最新市場趨勢

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最新趨勢
  • 主要的策略分析
  • COVID-19對主要企業的影響

第4章 市場決策要素

  • 成長要素
  • 阻礙因素
  • 市場機會

第5章 市場區隔

  • 各適應症的全球糖尿病腎病變市場
    • 第一型糖尿病
    • 第二型糖尿病
  • 各診斷的全球糖尿病腎病變市場
    • 尿液檢查
    • 影像檢查
    • 血液檢驗
    • 腎功能檢驗
    • 腎切片檢查
  • 各治療的全球糖尿病腎病變市場
    • 藥物療法
    • 腎臟透析
    • 腎臟移植

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • Abbott Laboratories
  • Abbvie, Inc.
  • Aerpio Pharmaceuticals, Inc.
  • Antisense Therapeutics, Ltd.
  • Astellas Pharma Europe, Ltd.
  • AstraZeneca plc.
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Cellmid, Ltd.
  • ChemoCentryx, Inc.
  • Concert Pharmaceuticals, Inc.
  • Daiichi Sankyo Co., Ltd.
  • DiaMedica Therapeutics, Inc.
  • Dimerix, Ltd.
  • Dong Wha Pharma Co., Ltd.
  • Eli Lilly And Co.
  • Evotec SE
  • Galectin Therapeutics, Inc.
  • GenKyoTex SA
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Glucox Biotech
  • GNI Group, Ltd.
  • Intercept Pharmaceuticals, Inc.
  • Inventiva SA
  • Johnson & Johnson Services, Inc.
  • Mesoblast, Ltd.
  • Mitsubishi Tanabe Pharma Europe, Ltd.
  • NOXXON Pharma Ag
  • XORTX Therapeutics, Inc.
目錄
Product Code: OMR2023732

Global Diabetic Nephropathy Market Size, Share & Trends Analysis Report by Indication (Diabetes Type-1, and Diabetes Type-2), By Diagnosis (Urine Test, Imaging Test, Blood Test, Renal Function Test, and Renal Biopsy), and By Treatment (Medications, Kidney Dialysis, Kidney Transplant) Forecast Period 2021-2027.

The global diabetic nephropathy market is anticipated to grow at a substantial CAGR of 5.3% during the forecast period. Major factors contributing to the growth of the global diabetic nephropathy market include the increasing prevalence of diabetic patients across the globe due to sedentary lifestyles and faulty dietary habits of the population across the globe. The high cost of imaging devices and the long duration of clinical trials are the major restraining factors of the market growth.

The COVID-19 pandemic and trade war between China and the US had significantly impacted the global diabetic nephropathy market. Medical equipment is manufactured in China, and China has been accused of the spread of COVID-19 due to which lots of nations across the globe had traded with China. Hence, this will greatly impact the market due to the supply chain disruption.

The global diabetic nephropathy market is segmented based on indication, diagnosis, and application. Based on the indication, the market is segmented into diabetes type-1, and diabetes type-2. Based on the diagnosis, the market is segmented into urine tests, imaging tests, blood tests, renal function tests, and renal biopsy. Apart from this, by application, the market is segmented into medications, kidney dialysis, and kidney transplant.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The region of Latin America has a high risk of cardiovascular and renal diseases. According to the National Centre of Biotechnology Information, 21% population of Chile had creatinine clearance below 80 ml/min. Around 14.2% of Chile's population, 9.2% of Mexico's population, and 8.6% of Argentina's population had reported proteinuria. This had increased the chronic kidney diseases in the region. However, the people there are health-conscious, thus generating huge opportunities for the diagnosis and treatment of diabetic nephropathy in the Latin American region.

The major companies serving the global diabetic nephropathy market include Abbott Laboratories, Bayer AG, AstraZeneca, Xortx Therapeutics Inc., GlaxoSmithKline plc, Astellas Pharma, Inc., and AbbVie Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. Huge numbers of clinical trials are in line under different phases which will bring revolutionary changes in the diabetic nephropathy market. For instance, In December 2019, SONAR had announced that canagliflozin was found effective in treating end-stage kidney diseases. This newly invented therapeutic agent reduces the risk of heart failure and cardiovascular deaths.

Research Methodology

The market study of the global diabetic nephropathy market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Diabetic Nephropathy Market Research and Analysis by Indication

Global Diabetic Nephropathy Market Research and Analysis by Diagnosis

Global Diabetic Nephropathy Market Research and Analysis by Treatment

The Report Covers

Comprehensive research methodology of the global diabetic nephropathy market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global diabetic nephropathy market.

Insights about market determinants that are stimulating the global diabetic nephropathy market.

Detailed and extensive market segments with the regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Diabetic Nephropathy Market
  • Recovery Scenario of Global Diabetic Nephropathy Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Diabetic Nephropathy Market by Indication
    • 5.1.1. Diabetes Type-1
    • 5.1.2. Diabetes Type-2
  • 5.2. Global Diabetic Nephropathy Market by Diagnosis
    • 5.2.1. Urine Test
    • 5.2.2. Imaging Test
    • 5.2.3. Blood Test
    • 5.2.4. Renal Function Test
    • 5.2.5. Renal Biopsy
  • 5.3. Global Diabetic Nephropathy Market by Treatment
    • 5.3.1. Medications
    • 5.3.2. Kidney Dialysis
    • 5.3.3. Kidney Transplant

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Abbvie, Inc.
  • 7.3. Aerpio Pharmaceuticals, Inc.
  • 7.4. Antisense Therapeutics, Ltd.
  • 7.5. Astellas Pharma Europe, Ltd.
  • 7.6. AstraZeneca plc.
  • 7.7. Bayer AG
  • 7.8. Bristol-Myers Squibb Co.
  • 7.9. Cellmid, Ltd.
  • 7.10. ChemoCentryx, Inc.
  • 7.11. Concert Pharmaceuticals, Inc.
  • 7.12. Daiichi Sankyo Co., Ltd.
  • 7.13. DiaMedica Therapeutics, Inc.
  • 7.14. Dimerix, Ltd.
  • 7.15. Dong Wha Pharma Co., Ltd.
  • 7.16. Eli Lilly And Co.
  • 7.17. Evotec SE
  • 7.18. Galectin Therapeutics, Inc.
  • 7.19. GenKyoTex SA
  • 7.20. Gilead Sciences, Inc.
  • 7.21. GlaxoSmithKline plc.
  • 7.22. Glucox Biotech
  • 7.23. GNI Group, Ltd.
  • 7.24. Intercept Pharmaceuticals, Inc.
  • 7.25. Inventiva SA
  • 7.26. Johnson & Johnson Services, Inc.
  • 7.27. Mesoblast, Ltd.
  • 7.28. Mitsubishi Tanabe Pharma Europe, Ltd.
  • 7.29. NOXXON Pharma Ag
  • 7.30. XORTX Therapeutics, Inc.

LIST OF TABLES

  • 1. GLOBAL DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 2. GLOBAL DIABETES TYPE-1 NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL DIABETES TYPE-2 NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 5. GLOBAL DIABETIC NEPHROPATHY URINE TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL DIABETIC NEPHROPATHY IMAGING TESTSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL DIABETIC NEPHROPATHYBLOOD TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL DIABETIC NEPHROPATHY RENAL FUNCTIONING TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL DIABETIC NEPHROPATHY RENAL BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 11. GLOBAL MEDICATIONS FOR DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL KIDNEY DIALYSISFOR DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL KIDNEY TRANSPLANTFOR DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 16. NORTH AMERICAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 18. NORTH AMERICAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 19. EUROPEAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 20. EUROPEAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 21. EUROPEAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 22. EUROPEAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 24. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 25. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 26. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 27. REST OF THE WORLD DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 28. REST OF THE WORLD DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 29. REST OF THE WORLD DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 30. REST OF THE WORLD DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL DIABETIC NEPHROPATHY MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL DIABETIC NEPHROPATHY MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL DIABETIC NEPHROPATHY MARKET, 2021-2027 (%)
  • 4. GLOBAL DIABETIC NEPHROPATHY MARKET SHARE BY INDICATION, 2020 VS 2027 (%)
  • 5. GLOBAL DIABETES TYPE-1 NEPHROPATHYMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 6. GLOBAL DIABETES TYPE-2 NEPHROPATHYMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 7. GLOBAL DIABETIC NEPHROPATHY MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 8. GLOBAL DIABETIC NEPHROPATHY URINE TESTFOR DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL IMAGING TESTFOR DIABETIC NEPHROPATHYMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL BLOOD TESTFOR DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL RENEAL FUNCTIONING TESTFOR DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBAL RENAL BIOPSYFOR DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBAL DIABETIC NEPHROPATHY MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 14. GLOBAL DIABETIC NEPHROPATHY MEDICATION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL DIABETIC NEPHROPATHY KIDNEY DIALYSIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. GLOBAL DIABETIC NEPHROPATHY KIDNEY TRANSPLANT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 17. GLOBAL DIABETIC NEPHROPATHY ACUPUNCTURE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 18. GLOBAL DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 19. US DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 20. CANADA DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. UK DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. ITALY DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. REST OF EUROPE DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. INDIA DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. CHINA DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. JAPAN DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. SOUTH KOREA DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. REST OF THE WORLD DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)